Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
Michelle K. Greene(Queen's University Belfast), Christopher J. Scott(Queen's University Belfast)
Cited by 19
Related Papers
A Population-Based Study of Genes Previously Implicated in Breast Cancer
|New England Journal of Medicine|2021|862
Cathepsin S expression: An independent prognostic factor in glioblastoma tumours—a pilot study
|International Journal of Cancer|2006|83
Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity
|Cell Death and Disease|2014|55